drugset / Trial / NCT05682495
A HR20031 BE Study on Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to assess the bioequivalence between HR20031 FDC tablet and co-administration of SHR3824 tablets, SP2086 tablets and metformin XR tablets.
Timeline
- Start
- 2023-01-31
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HR20031 | Unknown | 5 mg | — |
| Subject | HR20031 | Unknown | 10 mg | — |
| Subject | HR20031 | Unknown | 50 mg | — |
| Subject | HR20031 | Unknown | 100 mg | — |
| Subject | HR20031 | Unknown | 750 mg | — |
| Subject | HR20031 | Unknown | 1000 mg | — |
| Subject | Henagliflozin | Small molecule | 10 mg | — |
| Subject | Metformin | Small molecule | 1000 mg | — |
| Subject | Metformin | Small molecule | 1500 mg | — |
| Subject | Retagliptin | Small molecule | 100 mg | — |